To access this material please log in or register

Register Authorize

Case report of the sacubitril/valsartan treatment in a female patient with left ventricular noncompaction and developing anthr acycline car diomyopathy

Tereshchenko S. N., Uskach T. M., Safiullina A. A., Narusov O. Yu., Zhirov I. V., Saidova M. A., Zalesnova O. A.
Russian Cardiology Science and Production Center, 3rd Cherepkovskaya 15a, Moscow 121552, Russia

Keywords: noncompaction myocardium, left ventricle, antr acycline-induced cardiomyopathy, heart failure, sacubitril/valsartan, treatment

DOI: 10.18087/rhfj.2017.4.2375

The article describes the outcome of treatment with sacubitril/valsartan, a new drug from the group of angiotensin receptor‑neprilysin inhibitors (ARNI), in a female patient with heart failure and reduced LV EF secondary to anthracycline cardiomyopathy and LV noncompaction (LVNC).
  1. The Consensus Trial Study Group*. Effects of Enalapril on Mortality in Severe Congestive Heart Failure. New England Journal of Medicine. 1987;316(23):1429–35. DOI:10.1056/NEJM198706043162301.
  2. Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure. New England Journal of Medicine. 1991;325(5):293–302. DOI:10.1056/NEJM199108013250501.
  3. Cruden NLM, Fox KAA, Ludlam CA, Johnston NR , Newby DE. Neutral Endopeptidase Inhibition Augments Vascular Actions of Bradykinin in Patients Treated With Angiotensin‑Converting Enzyme Inhibition. Hypertension. 2004;44(6):913–8. DOI:10.1161/01.HYP.0000146483.78994.56.
  4. Rademaker MT, Charles CJ, Espiner EA, Nicholls MG, Richards AM, Kosoglou T. Combined Neutral Endopeptidase and Angiotensin‑Converting Enzyme Inhibition in Heart Failure: Role of Natriuretic Peptides and Angiotensin II: Journal of Cardiovascular Pharmacology. 1998;31(1):116–25. DOI:10.1097/00005344‑199801000‑00017.
  5. Trippodo NC, Fox M, Monticello TM, Panchal BC, Asaad MM. Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril. J Cardiovasc Pharmacol. 1999;34(6):782–90.
  6. Kostis JB, Packer M, Black HR , Schmieder R, Henry D, Levy E. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens. 2004;17(2):103–11.
  7. Packer M, Califf RM, Konstam MA, Krum H, McMurray JJ, Rouleau J‑L et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation. 2002;106(8):920–6.
  8. McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR et al. Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure. New England Journal of Medicine. 2014;371(11):993–1004. DOI:10.1056/NEJMoa1409077.
  9. Solomon SD, Claggett B, Desai AS, Packer M, Zile M, Swedberg K et al. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection FractionCLINICAL PERSPECTIVE: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM‑HF) Trial. Circulation: Heart Failure. 2016;9(3):e002744. DOI:10.1161/CIRCHEARTFAILURE.115.002744.
  10. Zile MR, Jhund PS, Baicu CF, Claggett BL, Pieske B, Voors AA et al. Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection FractionCLINICAL PERSPECTIVE: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study. Circulation: Heart Failure. 2016;9(1):e002551. DOI:10.1161/CIRCHEARTFAILURE.115.002551.
  11. Oechslin EN, Attenhofer Jost CH, Rojas JR , Kaufmann PA, Jenni R. Long‑term follow‑up of 34 adults with isolated left ventricular non‑compaction: a distinct cardiomyopathy with poor prognosis. J Am Coll Cardiol. 2000;36(2):493–500.
  12. Schwartzenberg S, Sherez J, Wexler D, Aviram G, Keren G. Isolated ventricular non‑compaction: an underdiagnosed cause of congestive heart failure. Isr Med Assoc J. 2009;11(7):426–9.
  13. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. Circulation. 1996;93(5):841–2. DOI:10.1161/01.CIR.93.5.841.
  14. Maron BJ. Contemporary Definitions and Classification of the Cardiomyopathies: An American Heart Association Scientific Statement From the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2006;113(14):1807–16. DOI:10.1161/CIRCULATIONAHA.106.174287.
  15. Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P et al. Classification of the cardiomyopathies: a position statement from the european society of cardiology working group on myocardial and pericardial diseases. European Heart Journal. 2007;29(2):270–6. DOI:10.1093/eurheartj/ehm342.
  16. Almeida AG, Pinto FJ. Non‑compaction cardiomyopathy. Heart. 2013;99(20):1535–42. DOI:10.1136/heartjnl‑2012‑302048.
  17. Pignatelli RH. Clinical Characterization of Left Ventricular Noncompaction in Children: A Relatively Common Form of Cardiomyopathy. Circulation. 2003;108(21):2672–8. DOI:10.1161/01.CIR.0000100664.10777.B8.
  18. Toste A, Branco LM, Galrinho A, Lousinha A, Fiarresga A, Oliveira MM et al. Noncompaction cardiomyopathy – a review of eight cases. Rev Port Cardiol. 2010;29(12):1847–64.
  19. Chin TK, Perloff JK, Williams RG, Jue K, Mohrmann R. Isolated noncompaction of left ventricular myocardium. A study of eight cases. Circulation. 1990;82(2):507–13. DOI:10.1161/01.CIR.82.2.507.
  20. Stöllberger C, Blazek G, Winkler‑Dworak M, Finsterer J. Sex Differences in Left Ventricular Noncompaction in Patients With and Without Neuromuscular Disorders. Revista Española de Cardiología (English Edition). 2008;61(2):130–6. DOI:10.1016/S1885‑5857(08)60088‑2.
  21. Ritter M, Oechslin E, Sütsch G, Attenhofer C, Schneider J, Jenni R. Isolated noncompaction of the myocardium in adults. Mayo Clin Proc. 1997;72(1):26–31. DOI:10.1016/S0025‑6196(11)64725‑3.
  22. Abbasi Y, Jabbari J, Jabbari R , Yang R‑Q, Risgaard B, Køber L et al. The pathogenicity of genetic variants previously associated with left ventricular non‑compaction. Molecular Genetics & Genomic Medicine. 2016;4(2):135–42. DOI:10.1002/mgg3.182.
  23. Carrilho‑Ferreira P, Almeida AG, Pinto FJ. Non‑compaction Cardiomyopathy: Prevalence, Prognosis, Pathoetiology, Genetics, and Risk of Cardioembolism. Current Heart Failure Reports. 2014;11(4):393–403. DOI:10.1007/s11897‑014‑0227‑3.
  24. Jenni R, Oechslin E, Schneider J, Attenhofer Jost C, Kaufmann PA. Echocardiographic and pathoanatomical characteristics of isolated left ventricular non‑compaction: a step towards classification as a distinct cardiomyopathy. Heart. 2001;86(6):666–71.
  25. Meinardi MT, Graaf WTA va. der, Veldhuisen DJ va., Gietema JA, Vries EGE d., Sleijfer DT. Detection of anthracycline‑induced cardiotoxicity. Cancer Treatment Reviews. 1999;25(4):237–47. DOI:10.1053/ctrv.1999.0128.
  26. Yeh ETH, Bickford CL. Cardiovascular Complications of Cancer Therapy. Journal of the American College of Cardiology. 2009;53(24):2231–47. DOI:10.1016/j.jacc.2009.02.050.
  27. Smith LA, Cornelius VR, Plummer CJ, Levitt G, Verrill M, Canney P et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta‑analysis of randomised controlled trials. BMC Cancer. 2010;10(1):337–50. DOI:10.1186/1471‑2407‑10‑337.
  28. Salvatorelli E, Menna P, Cantalupo E, Chello M, Covino E, Wolf FI et al. The concomitant management of cancer therapy and cardiac therapy. Biochimica et Biophysica Acta (BBA) ‑ Biomembranes. 2015;1848(10):2727–37. DOI:10.1016/j.bbamem.2015.01.003.
  29. Jones RL, Swanton C, Ewer MS. Anthracycline cardiotoxicity. Expert Opinion on Drug Safety. 2006;5(6):791–809. DOI:10.1517/14740338.5.6.791.
  30. Wasielewski M, van Spaendonck‑Zwarts KY, Westerink N‑DL, Jongbloed JDH, Postma A, Gietema JA et al. Potential genetic predisposition for anthracycline‑associated cardiomyopathy in families with dilated cardiomyopathy. Open Heart. 2014;1(1):e000116. DOI:10.1136/openhrt‑2014‑000116.
Tereshchenko S. N., Uskach T. M., Safiullina A. A., Narusov O. Yu., Zhirov I. V., Saidova M. A. et al. Case report of the sacubitril/valsartan treatment in a female patient with left ventricular noncompaction and developing anthracycline cardiomyopathy. Russian Heart Failure Journal. 2017;18(4):313–320

To access this material please log in or register

Register Authorize
Ru En